Partners Group: 2022 results are down sharply, but dividend is raised to CHF 37.
Regeneron announced Tuesday that Dupixent, its drug developed in partnership with Sanofi, has been approved in the European Union for the treatment of severe atopic dermatitis in children aged six months to five year…
© MarketScreener.com 2023
Regeneron announced Tuesday that Dupixent, its drug developed in partnership with Sanofi, has been approved in the European Union for the treatment of severe atopic dermatitis in children aged six months to five year…
© MarketScreener.com 2023